

## DIAGNOSIS OF CANDIDA VULVOVAGINITIS

To the Editor:

Vaginitis is a very common health problem, yet it can also be one of the most frustrating to patients and their physicians. Making a valid diagnosis based on symptoms and physical examination is difficult. Several studies have shown that the diagnosis of *Candida* vulvovaginitis based on clinical criteria is often erroneous compared with diagnosis by culture.<sup>1,2</sup> Since the routine use of vaginal cultures has not become the standard of care, however, diagnostic errors continue.

In the past, the symptom of vaginal itching has been attributed to *Candida* vulvovaginitis; but several studies suggest this complaint alone is not reliable.<sup>3-5</sup> Vaginal itching ranges from minimal discomfort to an overwhelming urge to scratch. After discussing the extent of itching with many patients over the years, we became aware of a subset of patients with severe itching who, in most cases, had culture-proven *Candida* infections. Those patients often expressed the desire to scratch with something (although few ever actually did so). We were eventually able to identify an object of appropriate shape and texture that women with this symptom agreed was what they desired—a picket fence. We termed this clue the "picket fence sign." We therefore designed the following study.

All patients with vaginal complaints were asked if they had itching. If they responded affirmatively, they were then asked if the itching was severe. Those who replied yes to this question were asked the following: "Some patients with vaginal itching have said they itched so bad that they wanted to scratch with a picket fence. Is this how you feel?" If the patient said no or was unsure, she was not entered in the study, and was evaluated and treated routinely in the office. If, however, she emphatically

agreed, a vaginal culture was added to the routine evaluation to identify *Candida albicans* as well as *Gardnerella vaginalis* in the vaginal discharge.

Of 11 consecutive patients admitted to the study, 10 were culture-positive for *Candida albicans* (a positive predictive value of 91%). The one patient with a negative culture did not have an obvious etiology by culture but did respond promptly to miconazole intravaginal cream.

The sensitivity of the picket fence sign cannot be determined from this study. Past studies indicate that itching of any degree may only be present in 50% of patients with *Candida* vulvovaginitis.<sup>3,5</sup> Therefore, the presence of severe itching would be present in an even lower percentage. Nevertheless, this study suggests that the presence of the picket fence sign in a woman with vaginal symptoms is highly predictive of *Candida* vulvovaginitis, and may obviate the need for culture confirmation prior to a course of presumptive treatment. We suggest further evaluation of this simple, rapid, in-office test for the differentiation of patients with symptomatic vaginitis.

Philip Zazove, MD  
West Jordan Medical Center  
Salt Lake City, Utah

Barbara D. Reed, MD, MSPH  
University of Utah Medical Center  
Salt Lake City, Utah

Werner Huck, M(ASCP)  
Hucsto, Inc.  
Salt Lake City, Utah

Stephen Stahl, MD  
West Jordan Medical Center  
Salt Lake City, Utah

### References

1. Berg AO, Heidrich FE, Fihn SD, et al: Establishing the cause of genitourinary symptoms in women in a family practice. *JAMA* 1984; 251:620-625
2. Reed BD, Huck W, Zazove P: Differentiation of *Gardnerella vaginalis*, *Candida albicans*, and *Trichomonas vaginalis* infec-

tions of the vagina. *J Fam Pract* 1989; 28:673-680

3. Bergman JJ, Berg AO: How useful are symptoms in the diagnosis of *Candida* vaginitis? *J Fam Pract* 1983; 16:509-511
4. Bertholf ME: Symptom diagnosis of *Candida* vaginitis, letter. *J Fam Pract* 1983; 17:776-777
5. Oriel JD, Partridge BM, Denny MJ, et al: Genital yeast infections. *Br Med J* 1972; 4:761-764

## OBSTETRICS IN FAMILY PRACTICE

We read with great interest "Present Status of Obstetrics in Family Practice and the Effects of Malpractice Issues" by Bredfeldt, Colliver, and Wesley in the March issue of the *Journal* (*J Fam Pract* 1989; 28:294-297). We would certainly agree with their premise that obstetrics remains an essential element of family medicine. We have recently conducted a survey of 1987 graduates of all of the family medicine training programs in the state of Georgia.<sup>1</sup>

Our data are in agreement with those of Bredfeldt and colleagues regarding the regional differences in the practice of obstetrics, especially regarding the southern region: only 21% of our responding graduates planned to include obstetrics in their practices.

Our data, however, suggested a significant difference with the conclusions of these authors about underlying causes for rejection of obstetric practice. We may be more in agreement with Klein,<sup>2</sup> who has suggested that malpractice issues are a "scapegoat" for the declining practice of obstetrics within family medicine. Our data clearly suggested that personal and professional lifestyle issues were at least as important as malpractice-litigation issues to our 1987 graduates who decided not to include obstetrics in their practice.

As Bredfeldt and colleagues have written, shrinking obstetric practice within family medicine is a complex issue. Likewise, it is doubtless the case



that malpractice-litigation issues have seriously contributed to the decline. However, and especially because politically active physicians have used declining numbers of physicians who are willing to deliver babies as a lever to influence legislative malpractice reform, we must be careful not to paint a distorted picture. Although recent legislative events have given hope for significant malpractice reform, we would suggest that other issues will need to be addressed by individuals entering the field of family medicine and by family medicine training programs before we see family physicians flocking back to the delivery suite. If and when our malpractice premiums ever decline, family physicians will still be faced with the question of whether they wish to leave their homes at night or a waiting room full of patients during office hours to go deliver a baby.

James L. Fletcher, Jr., MD  
Meyer P. Schwartz, MD  
Department of Family Medicine  
Medical College of Georgia  
Augusta

## References

1. Fletcher JL, Schwartz MP: Reasons why family medicine residents choose not to practice obstetrics. *J Med Assoc Ga*, in press
2. Klein M: Obstetrics is too important to be left to the obstetricians. *Fam Med* 1987; 19:167-169

## SMOKING AND GLYCOSYLATED HEMOGLOBIN

To the Editor:

The article by Urberg et al<sup>1</sup> on the effects of cigarette smoking on glycosylated hemoglobin is of great interest. A number of questions come to mind from this study.

First, it would have been helpful to further categorize the subjects of the study in terms of age, sex, weight, and other medical conditions that might lead to elevated glycosylated hemoglobin fractions (eg, iron deficiency anemia, splenectomy, hypertriglyceridemia, or alcoholism).

Second, while the normal fasting

blood glucose rules out overt diabetes, it does not preclude the possibility of occult impaired glucose tolerance. Glucose tolerance testing would have shed further light on the significance of their study.

Finally, it would lend further support to their conclusion if increasing fractions of glycosylated hemoglobin were found to correlate with increasing quantity of cigarette consumption. Cigarette consumption could be asayed in a variety of ways.

Until these questions are answered, the significance of this study remains uncertain.

Doug Trotter, MD  
Snohomish Family Medical Center  
Snohomish, Washington

## References

1. Urberg M, Shammas R, Rajdev K: The effects of cigarette smoking on glycosylated hemoglobin in nondiabetic individuals. *J Fam Pract* 1989; 28:529-531

*The preceding letter was referred to Dr. Urberg, who responds as follows:*

Dr. Trotter makes several significant comments about our article relating cigarette smoking to elevations in glycosylated hemoglobin levels in humans.

The subjects in our study were chosen to have normal cholesterol levels and to be different only in that some smoked one pack or more of cigarettes a day and the rest did not smoke at all. This was done to maximize the chances of finding a significant difference between the groups, and that difference was found. To our knowledge, age, sex, and weight have only small effects on glycosylated hemoglobin levels in normoglycemic subjects, and differences between smokers and nonsmokers in our subjects is unlikely to explain the magnitude of the effect seen. The effects of medical conditions on the level of glycosylated hemoglobin in normoglycemic individuals have not yet been systematically studied. Our subjects were in generally good health, however.

Normal fasting blood glucoses cannot rule out impairments in glucose tolerance; however, there is no reason

to believe that the normoglycemic smokers had a substantially greater incidence of impaired glucose metabolism than the nonsmokers in our study group. That fact that the smokers in our study had a slightly lower fasting glucose than the nonsmokers supports that conclusion. The glucose tolerance test is not a very sensitive measure of glucose metabolism in normal subjects. The literature on using glucose measurements to document a hyperglycemic effect of smoking was reviewed in the paper and was generally negative.

The problem of quantitating nicotine exposure in smokers is complicated. The number of cigarettes smoked per day is only an approximate measure. Smoking technique varies widely, as does the nicotine content of cigarettes. Nicotine blood levels are available from regional research laboratories, but are expensive. Further, the nicotine level of blood in smokers changes rapidly following smoking. Finally, since blood nicotine levels are very low, one must be scrupulously careful in protecting the blood samples from ambient cigarette smoke, which makes the determination of blood nicotine levels in an actively smoking subject technically difficult. To justify a study of such magnitude and cost, it is first necessary to demonstrate that smoking has a significant effect on blood glucose. This paper was intended to do just that.

Further studies are needed to address Dr. Trotter's questions. I would encourage him and other family physicians to carry out these studies.

Martin Urberg, MD, PhD  
Wayne State University  
Detroit, Michigan

## SERUM CHOLESTEROL AND GLYCOSYLATED HEMOGLOBIN

To the Editor:

This letter is in response to the three letters by Dr. Perez, Dr. Knudson and Dr. Neighbor (*Serum cholesterol and glycosylated hemoglobin. J Fam Pract* 1989; 28:731-732), which ap-



peared in the June issue of the Journal in response to our paper "A Correlation Between Serum Cholesterol and Glycosylated Hemoglobin in Non-diabetic Humans."<sup>1</sup>

Dr. Perez makes several valid observations about the relationship between glucose metabolism and disease. He cites one of Dr. Yudkin's many publications relating sugar intake to atherosclerosis. It is unclear why Dr. Yudkin has fallen into disfavor; however, as evidence relating glucose metabolism to atherosclerosis mounts, his work may be reexamined.

Dr. Knudson makes several editorial comments that reflect the very high standards of academic excellence which are coming to be accepted by the family practice community. These standards will serve us well as we move into the mainstream of academic medical research. His criticisms are, however, rather harsh and do not reflect the realities of the current state of knowledge regarding glycosylated hemoglobin levels in nondiabetic individuals. Subject selection in our study was consistent with the practice in other published studies in similar fields. Our study population was defined by age, sex, and the absence of diabetes or atherosclerotic heart disease. Further, no subject was taking any medications known to affect either glucose metabolism or cholesterol levels. A fasting blood glucose was measured to rule out any unknown diabetes. Sosenko et al<sup>2</sup> did not measure glucose levels at all. The selection of subjects was clearly described and was not random. Subjects were chosen to represent a wide range of cholesterol levels, while at the same time having no other known significant risk factors for atherosclerotic heart disease. This stratification by cholesterol levels was done to maximize the chance of finding a significant correlation if one existed. This strategy was successful, as the paper demonstrated. Studies that use different designs are likely to find smaller correlations between cholesterol and glycosylated hemoglobin.

Significant confounders for a study such as ours are many, and it is difficult to address all of them in a small

*continued on page 326*

#### KENALOG® SPRAY

Triamcinolone Acetonide Topical Aerosol USP  
For dermatologic use only

**DESCRIPTION**—Each gram of Kenalog Spray (Triamcinolone Acetonide Topical Aerosol USP) provides 0.147 mg triamcinolone acetonide in a vehicle of isopropyl palmitate, dehydrated alcohol (10.3%), and isobutane propellant.

**INDICATIONS AND USAGE**—Kenalog Spray (Triamcinolone Acetonide Topical Aerosol USP) is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

**CONTRAINDICATIONS**—Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

**PRECAUTIONS—General:** Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Patients receiving a large dose of any potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.

Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing material or adhesive and a substitute material may be necessary.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS, Pediatric Use).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

For dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

**Laboratory Tests**—A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating HPA axis suppression.

**Carcinogenesis, Mutagenesis, and Impairment of Fertility**—Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone showed negative results.

**Pregnancy—Teratogenic Effects:** Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

**Nursing Mothers**—It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

**Pediatric Use**—Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

Tight-fitting diapers or plastic pants should not be used on a child being treated in the diaper area, since these garments may constitute occlusive dressings.

**ADVERSE REACTIONS**—The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

**OVERDOSAGE**—Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS, General).

**DOSAGE AND ADMINISTRATION—Occlusive Dressing Technique:** Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Spray a small amount of the preparation onto the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply the spray under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional spray should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

**Consult package insert before prescribing Kenalog Spray (Triamcinolone Acetonide Topical Aerosol USP).**

(J3-232G)

© 1989 E.R. Squibb & Sons, Inc., Princeton, NJ  
329-501

Issued: June 1989



**TERAZOL\* 7 (terconazole) Vaginal Cream, 0.4%**  
**TERAZOL\* 3 (terconazole) Vaginal Suppositories, 80 mg**

**INDICATIONS AND USAGE:** TERAZOL 7 Vaginal Cream and TERAZOL 3 Vaginal Suppositories are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As TERAZOL 7 Vaginal Cream and TERAZOL 3 Vaginal Suppositories are effective only for vulvovaginitis caused by the genus *Candida*, the diagnosis should be confirmed by KOH smears and/or cultures.

**HUMAN PHARMACOLOGY:** Photosensitivity reactions were observed in some normal volunteers following repeated dermal application of terconazole 2.0% and 0.8% creams under conditions of filtered artificial ultraviolet light. Photosensitivity reactions have not been observed in U.S. and foreign clinical trials in patients who were treated with terconazole vaginal cream or suppositories.

**CONTRAINDICATIONS:** Patients known to be hypersensitive to terconazole or to any components of terconazole cream or suppositories.

**PRECAUTIONS:** **General:** Discontinue use and do not retreat with terconazole if sensitization, irritation, fever, chills or flu-like symptoms are reported during use.

The base contained in the TERAZOL 3 Vaginal Suppositories formulation may interact with certain rubber or latex products, such as those used in vaginal contraceptive diaphragms, therefore concurrent use is not recommended.

If there is lack of response to TERAZOL 7 Vaginal Cream or TERAZOL 3 Vaginal Suppositories, appropriate microbiological studies (standard KOH smear and/or cultures) should be repeated to confirm the diagnosis and rule out other pathogens.

**Drug Interactions:** The therapeutic effect of TERAZOL 7 Vaginal Cream and TERAZOL 3 Vaginal Suppositories is not affected by oral contraceptive usage.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:**

**Carcinogenesis:** Studies to determine the carcinogenic potential of terconazole have not been performed.

**Mutagenicity:** Terconazole was not mutagenic when tested *in vitro* for induction of microbial point mutations (Ames test) or for inducing cellular transformation, or *in vivo* for chromosome breaks (micronucleus test) or dominant lethal mutations in mouse germ cells.

**Impairment of Fertility:** No impairment of fertility occurred when female rats were administered terconazole orally up to 40 mg/kg/day.

**Pregnancy:** **Pregnancy Category C:** There was no evidence of teratogenicity when terconazole was administered orally up to 40 mg/kg/day (TERAZOL 7 Vaginal Cream—100x the recommended intravaginal human dose; TERAZOL 3 Vaginal Suppositories—25x the recommended intravaginal human dose) in rats, or 20 mg/kg/day in rabbits, or subcutaneously in rats up to 20 mg/kg/day.

Dosages at or below 10 mg/kg/day produced no embryotoxicity; however, there was a delay in fetal ossification at 10 mg/kg/day in rats. There was some evidence of embryotoxicity in rabbits and rats at 20-40 mg/kg. In rats this was reflected as a decrease in litter size and number of viable young and reduced fetal weight. There was also delay in ossification and an increased incidence of skeletal variants.

The no-effect oral dose of 10 mg/kg/day resulted in a mean peak plasma level of terconazole in pregnant rats of 0.176 mcg/ml which exceeds by 44 times the mean peak plasma levels (0.004 mcg/ml) seen in normal subjects after intravaginal administration of terconazole. This assessment does not account for possible exposure of the fetus through direct transfer of terconazole from the irritated vagina to the fetus by diffusion across amniotic membranes.

Since terconazole is absorbed from the human vagina, it should not be used in the first trimester of pregnancy unless the physician considers it essential to the welfare of the patient.

**Nursing Mothers:** TERAZOL 7 Vaginal Cream—It is not known whether this drug is excreted in human milk. Animal studies have shown that rat offspring exposed via the milk of treated (40 mg/kg/orally) dams showed decreased survival during the first few post-partum days, but overall pup weight and weight gain were comparable to or greater than controls throughout lactation.

TERAZOL 3 Vaginal Suppositories—It is not known whether terconazole is excreted in human milk. Animal studies have shown that rat offspring exposed via the milk of treated (40 mg/kg/orally) dams showed decreased survival during the first few post-partum days.

TERAZOL 7 Vaginal Cream and TERAZOL 3 Vaginal Suppositories—Because many drugs are excreted in human milk, and because of the potential for adverse reaction in nursing infants from terconazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatric Use:** Safety and efficacy in children have not been established.

**ADVERSE REACTIONS:** TERAZOL 7 Vaginal Cream—During controlled clinical studies conducted in the United States, 521 patients with vulvovaginal candidiasis were treated with terconazole 0.4% vaginal cream. Based on comparative analyses with placebo, the adverse experiences considered most likely related to terconazole 0.4% vaginal cream were headache (26% vs 17% with placebo) and body pain (2.1% vs 0% with placebo). Vulvovaginal burning (5.2%), itching (2.3%) or irritation (3.1%) occurred less frequently with terconazole 0.4% vaginal cream than with the vehicle placebo. Fever (1.7% vs 0.5% with placebo) and chills (0.4% vs 0.0% with placebo) have also been reported. The therapy-related dropout rate was 1.9%. The adverse drug experience on terconazole most frequently causing discontinuation was vulvovaginal itching (0.6%), which was lower than the incidence for placebo (0.9%).

TERAZOL 3 Vaginal Suppositories—During controlled clinical studies conducted in the United States, 284 patients with vulvovaginal candidiasis were treated with terconazole 80 mg vaginal suppositories. Based on comparative analyses with placebo (295 patients), the adverse experiences considered adverse reactions most likely related to terconazole 80 mg vaginal suppositories were headache (30.3% vs 20.7% with placebo), and pain of the female genitalia (4.2% vs 0.7% with placebo). Adverse reactions that were reported but were not statistically significantly different from placebo were burning (15.2% vs 11.2% with placebo) and body pain (3.9% vs 1.7% with placebo). Fever (2.8% vs 1.4% with placebo) and chills (1.8% vs 0.7% with placebo) have also been reported. The therapy-related dropout rate was 3.5% and the placebo therapy-related dropout rate was 2.7%. The adverse drug experience on terconazole most frequently causing discontinuation was burning (2.5% vs 1.4% with placebo) and pruritus (1.8% vs 1.4% with placebo).

Revised 12/88

ORTHO PHARMACEUTICAL CORPORATION  
Raritan, New Jersey 08869-0602



## LETTERS TO THE EDITOR

*continued from page 241*

study with limited resources. Further, it is becoming clear that we do not know which confounders are significant in studies of glycosylated hemoglobin in a nondiabetic population. Barrett-Connor et al<sup>3</sup> found no significant correlation between age and Hb A<sub>1c</sub>, and this finding has been confirmed in other studies recently. Cigarette smoking, on the other hand, has a profound effect on glycosylated hemoglobin in normoglycemic, normocholesterolemic subjects.<sup>4</sup> Smoking was not addressed by Sosenko et al<sup>2</sup> nor by Barrett-Connor et al.<sup>3</sup> We had three smokers in our study, all of whom had higher glycosylated hemoglobin levels than would be expected from their cholesterol levels. Including significant numbers of smokers in the study group would be expected to decrease the observed correlation between glycosylated hemoglobin and cholesterol. We did not control for obesity, but most of our subjects were normal weight. Obesity did not significantly affect the magnitude of the Hb A<sub>1c</sub> cholesterol correlation in the study of Barrett-Connor et al,<sup>3</sup> however.

The paper by Barrett-Connor et al<sup>3</sup> came to my attention after our paper appeared in print. This is unfortunate because their results complement ours, and because Barrett-Connor is one of the most prominent researchers in family medicine. They found significant positive correlations between total cholesterol and Hb A<sub>1c</sub> for men ( $r = .12$ ) and for women ( $r = .20$ ) which are consistent with our findings but of much smaller magnitude. There are several differences in the two study designs, which may account for the differences in correlation coefficients found. First, they used Hb A<sub>1c</sub> as their measure of glycosylated hemoglobin, while we used the boronate affinity gel technique. While the latter technique is more precise, Hb A<sub>1c</sub> correlates quite well with average blood glucose. Second, while the number of smokers in our study was small, we do not know the number of smokers in their study. Third, and perhaps most important, we took 5.83 mmol/L (105 mg/dL) as the upper limit of normal for serum glucose, while they used 7.78 mmol/L (140 mg/dL) as

the upper limit of normal. Since subjects with fasting glucose levels in the range of 5.83 mmol/L and 7.78 mmol/L are likely to have mild impairments in glucose tolerance, it is not clear that the relationship of glycosylated hemoglobin to total cholesterol for these subjects is the same as in subjects with normal fasting glucose levels. Glycosylated hemoglobin is expected to be high in these subjects, but cholesterol may not be elevated as well.

The most significant findings in the study of Barrett-Connor et al<sup>3</sup> are that with a different study design which asked a different question than our study, they found a significant correlation between glycosylated hemoglobin and cholesterol, which is in the same direction as ours. Further, they were able to document the fact that age and obesity do not substantially detract from that correlation. Their study supports the general conclusions of our report.

Dr. Neighbor calculated the slope of the regression line between cholesterol and glycosylated hemoglobin in our study and found it to be substantially greater than that calculated from that data of Barrett-Connor et al.<sup>3</sup> This is an example of the phenomenon of regression toward the mean,<sup>5</sup> and is due to the fact that our correlation coefficient is greater than theirs.

Martin Urberg, MD, PhD  
Wayne State University  
Detroit, Michigan

## References

1. Urberg M, Rajdev K: A correlation between serum cholesterol and glycosylated hemoglobin in nondiabetic humans. *J Fam Pract* 1989; 28:269-274
2. Sosenko JM, Kubrusly DB, Goldberg RB, et al: High-density lipoprotein and glycosylated hemoglobin in nondiabetic individuals. *Ann Intern Med* 1986; 104:1521-1524
3. Barrett-Connor E, Criqui MH, Witztum JL, et al: Population-based study of glycosylated hemoglobin lipids and lipoproteins in nondiabetic adults. *Atherosclerosis* 1987; 7:66-70
4. Urberg M, Shammas R, Rajdev K: The effects of cigarette smoking on glycosylated hemoglobin in nondiabetic individuals. *J Fam Pract* 1989; 28:529-531
5. Hays WL: *Statistics*, ed 4, New York, Holt Rinehart and Winston, 1988, pp 560-562